Study: NCT03833362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Narlaprevir
Description: yellow film-coated 100 mg. tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Narlaprevir
Description: yellow film-coated 100 mg. tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100 mg tablets encapsulates in gelatin capsules (for blinding purposes)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100 mg tablets encapsulates in gelatin capsules (for blinding purposes)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Narlaprevir
Description: yellow film-coated 100 mg. tablets identical to Narlaprevir tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Narlaprevir
Description: yellow film-coated 100 mg. tablets identical to Narlaprevir tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Ritonavir
Description: 100 mg lactose/ cellulose tablets encapsulated in gelatin capsules (for blinding purposes) identical to Ritonavir capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Ritonavir
Description: 100 mg lactose/ cellulose tablets encapsulated in gelatin capsules (for blinding purposes) identical to Ritonavir capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b
Description: 180µg for subcutaneous injections in 0.5 ml syrettes / 1.5 µg/kg for subcutaneous injections in 50µkg, 80µkg,100µkg, 120µkg, 150µkg in vials

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b
Description: 180µg for subcutaneous injections in 0.5 ml syrettes / 1.5 µg/kg for subcutaneous injections in 50µkg, 80µkg,100µkg, 120µkg, 150µkg in vials

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b
Description: 180µg for subcutaneous injections in 0.5 ml syrettes / 1.5 µg/kg for subcutaneous injections in 50µkg, 80µkg,100µkg, 120µkg, 150µkg in vials

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b
Description: 180µg for subcutaneous injections in 0.5 ml syrettes / 1.5 µg/kg for subcutaneous injections in 50µkg, 80µkg,100µkg, 120µkg, 150µkg in vials

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: hard gelatin, white 200mg. capsules~Weight-based dose was 1000 mg/day (patient weight \<75 kg) or 1200 mg/day (patient weight ≥75 kg) with Peginterferon alfa-2a and 800 mg/day (patient weight \<65 kg) - 1400 (patient weight \>105 kg) mg/day with Peginterferon alfa-2b

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: hard gelatin, white 200mg. capsules~Weight-based dose was 1000 mg/day (patient weight \<75 kg) or 1200 mg/day (patient weight ≥75 kg) with Peginterferon alfa-2a and 800 mg/day (patient weight \<65 kg) - 1400 (patient weight \>105 kg) mg/day with Peginterferon alfa-2b

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: hard gelatin, white 200mg. capsules~Weight-based dose was 1000 mg/day (patient weight \<75 kg) or 1200 mg/day (patient weight ≥75 kg) with Peginterferon alfa-2a and 800 mg/day (patient weight \<65 kg) - 1400 (patient weight \>105 kg) mg/day with Peginterferon alfa-2b

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: hard gelatin, white 200mg. capsules~Weight-based dose was 1000 mg/day (patient weight \<75 kg) or 1200 mg/day (patient weight ≥75 kg) with Peginterferon alfa-2a and 800 mg/day (patient weight \<65 kg) - 1400 (patient weight \>105 kg) mg/day with Peginterferon alfa-2b